JBIO NASDAQ
Jade Biosciences, Inc.
1W: -4.0%
1M: -10.4%
3M: -26.6%
YTD: +39.1%
1Y: +137.9%
$19.70
-0.25 (-1.25%)
Weekly Expected Move ±7.3%
$17
$19
$20
$22
$23
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$642.7M
52W Range6.67-28
Volume766,528
Avg Volume1,040,585
Beta1.43
Dividend$2.40
Analyst Ratings
Company Info
CEOTom Frohlich
Employees55
SectorHealthcare
IndustryBiotechnology
IPO Date2021-06-30
Websitejadebiosciences.com
221 Crescent Street Building 23
Waltham, MA 02453
US
Waltham, MA 02453
US
1 916-322-1700
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
Latest News
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Stock Market Today: S&P 500 Futures Fall, Dow Gains As House Challenges Trump's Military Authority—Broadcom, CrowdStrike, Lululemon In Focus
Ciena, Docusign And 3 Stocks To Watch Heading Into Thursday
Jade Biosciences prices $150M public offering of common stock at $15/share
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Eisner Mark | 0 | — | 2026-06-25 | |
| Eisner Mark | A-Award | 47,675 | $21.81 | 2026-06-25 |
| CAIN CHRISTOPHER W. | A-Award | 34,843 | $15.22 | 2026-06-09 |
| DOBMEIER ERIC | A-Award | 34,843 | $15.22 | 2026-06-09 |
| Klein Lawrence Otto | A-Award | 34,843 | $15.22 | 2026-06-09 |